The EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support

Authors

  • Kerolos Wagdy Aswan Heart Center, Division of Cardiology, Aswan, Egypt

DOI:

https://doi.org/10.21542/gcsp.2020.31

Abstract

[no abstract - showing first paragraph]

Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a relatively new class of antihyperglycemic medication that are well established for the management of type-2 diabetes mellitus (DM). They have a unique mechanism of action that targets the kidneys through inhibition of 90% of glucose reabsorption.

Downloads

Published

2020-12-30

Issue

Vol. 2020 No. 3 (2020)

Section

Lessons from the trials

License

This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.